Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XB 002

Next Previous
Search
Drug Profile

XB 002

Alternative Names: ICON-2; ICON2 Tissue Factor ADC; Tissue factor antibody drug conjugate - Iconic Therapeutics; XB-002 ; XB002 Tissue Factor ADC

Latest Information Update: 20 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Iconic Therapeutics
  • Developer Exelixis
  • Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 10 Mar 2025 Exelixis completes a phase I trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Combination therapy, Recurrent) in South Korea (IV) (NCT04925284)
  • 06 Aug 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in USA, South Korea, Australia, Belgium, Italy, France, Netherlands, Spain, United Kingdom (IV)
  • 06 Aug 2024 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in United Kingdom, Spain, Netherlands, Italy, France, Belgium, Australia, South Korea, South Korea, USA (IV)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top